You are here: Industry Insights > Ocugen

News List

Ocugen, Bharat Biotech sign agreement for commercialisation rights to COVAXIN in Canada expresspharma
June 04, 2021
Similar to the US profit share arrangement, Ocugen will retain 45 per cent of the profits from sales of COVAXIN in Canada.
Ocugen intends to sell 100 million doses of COVAXIN in US in 2021 expresspharma
March 17, 2021
Ocugen plans to sell 100 million doses of India’s Covaxin in the US this year, Shankar Musunuri, CEO of the company told Reuters.
Ocugen’s inherited retinal disease gene therapy OCU400 wins orphan status pharmatimes
February 25, 2021
The European Commission (EC) has granted Ocugen’s gene therapy candidate OCU400 an orphan medicinal product designation for the treatment of the inherited retinal diseases (IRDs) retinitis pigmentosa and Leber Congenital amaurosis.
Ocugen, Bharat Biotech announce agreement for commercialisation of Covaxin in US market expresspharma
February 03, 2021
Ocugen is also in active discussions with manufacturers in the US to produce a significant number of doses of COVAXIN to support its US immunisation programme.
Ocugen and Bharat Biotech to Co-develop COVAXIN for US market expresspharma
December 23, 2020
Companies will co-develop inactivated vaccine candidate, COVAXIN™, to prevent COVID-19 infection in the U.
Ocugen expands global patent portfolio for OCU200 pharmasia
May 25, 2017
Company receives patents in US and Japan and notice of intent to grant patent in EU.

Previous page 1 2 Next page